{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:54:01Z","timestamp":1761544441958,"version":"build-2065373602"},"reference-count":18,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,1,1]],"date-time":"2021-01-01T00:00:00Z","timestamp":1609459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","japha.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the American Pharmacists Association"],"published-print":{"date-parts":[[2021,1]]},"DOI":"10.1016\/j.japh.2020.07.017","type":"journal-article","created":{"date-parts":[[2020,8,10]],"date-time":"2020-08-10T18:36:54Z","timestamp":1597084614000},"page":"e53-e56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["Clozapine-induced pulmonary embolism in a patient with minimal pre-existing risk factors"],"prefix":"10.1016","volume":"61","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2278-1018","authenticated-orcid":false,"given":"Kristin","family":"Waters","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9067-3054","authenticated-orcid":false,"given":"Heather","family":"Goodwin","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2276-897X","authenticated-orcid":false,"given":"Gina","family":"Morrow","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.japh.2020.07.017_bib1","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40263-018-0495-7","article-title":"Venous thromboembolism during treatment with antipsychotics: a review of current evidence","volume":"32","author":"J\u00f6nsson","year":"2018","journal-title":"CNS Drugs"},{"issue":"8","key":"10.1016\/j.japh.2020.07.017_bib2","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/11633920-000000000-00000","article-title":"Venous thromboembolism in recipients of antipsychotics: incidence, mechanisms and management","volume":"26","author":"J\u00f6nsson","year":"2012","journal-title":"CNS Drugs"},{"key":"10.1016\/j.japh.2020.07.017_bib3","doi-asserted-by":"crossref","first-page":"c4245","DOI":"10.1136\/bmj.c4245","article-title":"Antipsychotic drugs and risk of venous thromboembolism: nested case-control study","volume":"341","author":"Parker","year":"2010","journal-title":"BMJ"},{"issue":"9237","key":"10.1016\/j.japh.2020.07.017_bib4","doi-asserted-by":"crossref","first-page":"1219","DOI":"10.1016\/S0140-6736(00)02784-7","article-title":"Antipsychotic drug use and risk of first-time idiopathic venous thromboembolism: a case-control study","volume":"356","author":"Zornberg","year":"2000","journal-title":"Lancet"},{"issue":"9210","key":"10.1016\/j.japh.2020.07.017_bib5","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1016\/S0140-6736(00)02066-3","article-title":"Association of venous thromboembolism and clozapine","volume":"355","author":"H\u00e4gg","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.japh.2020.07.017_bib6","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1111\/j.1440-1819.2007.01773.x","article-title":"Assessment of risk of venous thromboembolism and its possible prevention in psychiatric patients","volume":"62","author":"Mal\u00fd","year":"2008","journal-title":"Psychiatry Clin Neurosci"},{"issue":"4","key":"10.1016\/j.japh.2020.07.017_bib7","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1176\/ajp.152.4.651a","article-title":"Mortality risk and clozapine","volume":"152","author":"Clardy","year":"1995","journal-title":"Am J Psychiatry"},{"issue":"6","key":"10.1016\/j.japh.2020.07.017_bib8","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1097\/00001648-199710000-00010","article-title":"Mortality in current and former users of clozapine","volume":"8","author":"Walker","year":"1997","journal-title":"Epidemiology"},{"issue":"2","key":"10.1016\/j.japh.2020.07.017_bib9","first-page":"175","article-title":"Thrombotic complications of treatment with antipsychotic drugs","volume":"104","author":"Shulman","year":"2013","journal-title":"Minerva Med"},{"issue":"4","key":"10.1016\/j.japh.2020.07.017_bib10","doi-asserted-by":"crossref","first-page":"e434","DOI":"10.1097\/MJT.0000000000000806","article-title":"Clozapine-associated pulmonary embolism: a high-mortality, dose-independent and early-onset adverse effect","volume":"25","author":"Sarvaiya","year":"2018","journal-title":"Am J Ther"},{"issue":"19","key":"10.1016\/j.japh.2020.07.017_bib11","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.2146\/ajhp070638","article-title":"Evaluating the association between clozapine and venous thromboembolism","volume":"65","author":"Paciullo","year":"2008","journal-title":"Am J Health Syst Pharm"},{"issue":"3","key":"10.1016\/j.japh.2020.07.017_bib12","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.pharep.2017.12.003","article-title":"The impact of antipsychotics as a risk factors for thromboembolism","volume":"70","author":"Og\u0142odek","year":"2018","journal-title":"Pharmacol Rep"},{"issue":"5","key":"10.1016\/j.japh.2020.07.017_bib13","first-page":"421","article-title":"The effects of novel and newly approved antipsychotics on serum prolactin levels: a comprehensive review","volume":"28","author":"Peuskens","year":"2014","journal-title":"CNS Drugs"},{"key":"10.1016\/j.japh.2020.07.017_bib14","series-title":"Antipsychotics: Treating Psychosis, Mania and Depression","first-page":"33","article-title":"Chapter 2. Multifuntionality of antipsychotics","author":"Stahl","year":"2010"},{"issue":"3","key":"10.1016\/j.japh.2020.07.017_bib15","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1007\/s13311-017-0552-9","article-title":"Clozapine as a model for antipsychotic development","volume":"14","author":"Nucifora","year":"2017","journal-title":"Neurotherapeutics"},{"issue":"2","key":"10.1016\/j.japh.2020.07.017_bib16","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/clpt.1981.154","article-title":"A\u00a0method for estimating the probability of adverse drug reactions","volume":"30","author":"Naranjo","year":"1981","journal-title":"Clin. Pharmacol. Ther"},{"issue":"1","key":"10.1016\/j.japh.2020.07.017_bib17","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/pds.2210","article-title":"Antipsychotic drugs and risk of pulmonary embolism","volume":"21","author":"Allenet","year":"2012","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"7","key":"10.1016\/j.japh.2020.07.017_bib18","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1093\/ijnp\/pyx019","article-title":"Potential role of patients\u2019 CYP3A-status in clozapine pharmacokinetics","volume":"20","author":"T\u00f3th","year":"2017","journal-title":"Int J Neuropsychopharmacol"}],"container-title":["Journal of the American Pharmacists Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319120303423?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1544319120303423?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T05:48:58Z","timestamp":1761544138000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1544319120303423"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,1]]}},"alternative-id":["S1544319120303423"],"URL":"https:\/\/doi.org\/10.1016\/j.japh.2020.07.017","relation":{},"ISSN":["1544-3191"],"issn-type":[{"type":"print","value":"1544-3191"}],"subject":[],"published":{"date-parts":[[2021,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clozapine-induced pulmonary embolism in a patient with minimal pre-existing risk factors","name":"articletitle","label":"Article Title"},{"value":"Journal of the American Pharmacists Association","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.japh.2020.07.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 American Pharmacists Association\u00ae. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}